CN102036989B - 6-杂芳基咪唑并[1,2-a]吡啶的多取代衍生物及其制备方法和治疗用途 - Google Patents

6-杂芳基咪唑并[1,2-a]吡啶的多取代衍生物及其制备方法和治疗用途 Download PDF

Info

Publication number
CN102036989B
CN102036989B CN200980118584.XA CN200980118584A CN102036989B CN 102036989 B CN102036989 B CN 102036989B CN 200980118584 A CN200980118584 A CN 200980118584A CN 102036989 B CN102036989 B CN 102036989B
Authority
CN
China
Prior art keywords
imidazo
pyridine
methyl alcohol
compound
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980118584.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN102036989A (zh
Inventor
丹妮尔·德佩雷蒂
扬妮克·伊瓦诺
戴维·马科尼克
纳萨利·拉科托阿里索
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39764971&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102036989(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of CN102036989A publication Critical patent/CN102036989A/zh
Application granted granted Critical
Publication of CN102036989B publication Critical patent/CN102036989B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN200980118584.XA 2008-03-21 2009-03-20 6-杂芳基咪唑并[1,2-a]吡啶的多取代衍生物及其制备方法和治疗用途 Expired - Fee Related CN102036989B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0801585 2008-03-21
FR0801585A FR2928924B1 (fr) 2008-03-21 2008-03-21 Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique
PCT/FR2009/000298 WO2009144392A1 (fr) 2008-03-21 2009-03-20 DÉRIVÉS POLYSUBSTITUES DE 6-HETEROARYLE-IMIDAZO[1,2-α]PYRIDINES, LEUR PRÉPARATION ET LEUR APPLICATION EN THÉRAPEUTIQUE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201310049249.7A Division CN103145747B (zh) 2008-03-21 2009-03-20 6-杂芳基咪唑并[1,2-a]吡啶的多取代衍生物及其制备方法和治疗用途

Publications (2)

Publication Number Publication Date
CN102036989A CN102036989A (zh) 2011-04-27
CN102036989B true CN102036989B (zh) 2014-05-07

Family

ID=39764971

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200980118584.XA Expired - Fee Related CN102036989B (zh) 2008-03-21 2009-03-20 6-杂芳基咪唑并[1,2-a]吡啶的多取代衍生物及其制备方法和治疗用途
CN201310049249.7A Expired - Fee Related CN103145747B (zh) 2008-03-21 2009-03-20 6-杂芳基咪唑并[1,2-a]吡啶的多取代衍生物及其制备方法和治疗用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201310049249.7A Expired - Fee Related CN103145747B (zh) 2008-03-21 2009-03-20 6-杂芳基咪唑并[1,2-a]吡啶的多取代衍生物及其制备方法和治疗用途

Country Status (24)

Country Link
US (2) US8088765B2 (enExample)
EP (1) EP2262804B1 (enExample)
JP (1) JP5508384B2 (enExample)
KR (1) KR20100124830A (enExample)
CN (2) CN102036989B (enExample)
AR (1) AR070995A1 (enExample)
AU (1) AU2009253232B2 (enExample)
BR (1) BRPI0910309A2 (enExample)
CA (1) CA2719118C (enExample)
CL (1) CL2009000699A1 (enExample)
CO (1) CO6300864A2 (enExample)
EA (1) EA201071111A1 (enExample)
FR (1) FR2928924B1 (enExample)
IL (1) IL208247A0 (enExample)
MA (1) MA32248B1 (enExample)
ME (1) ME01112B (enExample)
MX (1) MX2010010268A (enExample)
NZ (1) NZ588083A (enExample)
PE (1) PE20091694A1 (enExample)
PH (1) PH12012501817A1 (enExample)
TW (1) TW200942541A (enExample)
UY (1) UY31730A (enExample)
WO (1) WO2009144392A1 (enExample)
ZA (1) ZA201006725B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2928922B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines polysubstitues, leur preparation et leur application en therapeutique
FR2928923B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques
CN102131801B (zh) 2008-06-25 2015-04-08 福拉姆医药股份有限公司 1,2-二取代的杂环化合物
TWI453207B (zh) * 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
SI2617420T1 (sl) 2009-05-07 2016-02-29 Forum Pharmaceuticals Inc. Fenoksimetil heterociklične spojine
FR2953520B1 (fr) * 2009-12-04 2011-11-25 Sanofi Aventis Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique
TWI429628B (zh) 2010-03-29 2014-03-11 Univ Taipei Medical 吲哚基或吲哚啉基羥肟酸化合物
KR101594002B1 (ko) 2010-10-06 2016-02-15 글락소스미스클라인 엘엘씨 Ｐｉ３ 키나제 억제제로서의 벤즈이미다졸 유도체
US8975276B2 (en) 2011-06-29 2015-03-10 Bristol-Myers Squibb Company Inhibitors of PDE10
CN103214481B (zh) * 2012-01-21 2016-08-03 中国科学院上海药物研究所 新型咪唑并[1,2-a]吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
MD3377488T2 (ro) 2015-11-19 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
ES2916874T3 (es) 2015-12-17 2022-07-06 Incyte Corp Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
CA3009474A1 (en) 2015-12-22 2017-06-29 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EP3464279B1 (en) 2016-05-26 2021-11-24 Incyte Corporation Heterocyclic compounds as immunomodulators
SG11201811414TA (en) 2016-06-20 2019-01-30 Incyte Corp Heterocyclic compounds as immunomodulators
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
US20180057486A1 (en) 2016-08-29 2018-03-01 Incyte Corporation Heterocyclic compounds as immunomodulators
CN106631970A (zh) * 2016-12-14 2017-05-10 贵州大学 一种6‑苯甲酰基‑1h‑吲哚的制备方法
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
US10308644B2 (en) 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
EP4223369A1 (en) 2016-12-22 2023-08-09 Incyte Corporation Immunomodulator compounds and methods of use
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
SMT202300065T1 (it) 2018-03-30 2023-05-12 Incyte Corp Composti eterociclici come immunomodulatori
CN112752756B (zh) 2018-05-11 2024-06-25 因赛特公司 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物
TW202115059A (zh) 2019-08-09 2021-04-16 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之鹽
JP7559059B2 (ja) 2019-09-30 2024-10-01 インサイト・コーポレイション 免疫調節剤としてのピリド［３，２－ｄ］ピリミジン化合物
EP4058461A1 (en) 2019-11-11 2022-09-21 Incyte Corporation Salts and crystalline forms of a pd-1/pd-l1 inhibitor
US20230255934A1 (en) * 2020-04-24 2023-08-17 The Regents Of The University Of California Nurr1 receptor modulators and uses thereof
IL302590A (en) 2020-11-06 2023-07-01 Incyte Corp Process for preparing PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
US20240294529A1 (en) * 2021-07-16 2024-09-05 Sanofi 6h-imidazo[1,2-a]pyrrolo[2,3-e]pyridine derivatives for use in therapy
CN117916240A (zh) 2021-07-16 2024-04-19 赛诺菲 用于疗法的咪唑并[1,2-b][1,2,4]三唑衍生物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2903105A1 (fr) * 2006-07-03 2008-01-04 Sanofi Aventis Sa Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique
FR2903107A1 (fr) * 2006-07-03 2008-01-04 Sanofi Aventis Sa Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2476667E (pt) 2003-02-26 2014-09-18 Sugen Inc Compostos de aminoheteroarilo como inibidores da proteína quinase
FR2906250B1 (fr) * 2006-09-22 2008-10-31 Sanofi Aventis Sa Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique
US8338437B2 (en) * 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
FR2928922B1 (fr) 2008-03-21 2010-04-23 Sanofi Aventis Derives de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines polysubstitues, leur preparation et leur application en therapeutique
FR2928921B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines, leur preparation et leur application en therapeutique
FR2928923B1 (fr) * 2008-03-21 2010-04-23 Sanofi Aventis Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2903105A1 (fr) * 2006-07-03 2008-01-04 Sanofi Aventis Sa Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique
FR2903107A1 (fr) * 2006-07-03 2008-01-04 Sanofi Aventis Sa Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Microwave-Assisted Preparation of Fused Bicyclic Heteroaryl Boronates:Application in One-Pot Suzuki Couplings;Erin F. DiMauro et al.;《JOURNAL OF ORGANIC CHEMISTRY》;20060414;第71卷(第10期);第3959-3962页 *

Also Published As

Publication number Publication date
CN103145747B (zh) 2015-06-17
CN102036989A (zh) 2011-04-27
BRPI0910309A2 (pt) 2015-09-29
PE20091694A1 (es) 2009-11-20
MX2010010268A (es) 2011-04-05
EP2262804A1 (fr) 2010-12-22
AU2009253232A1 (en) 2009-12-03
EP2262804B1 (fr) 2014-12-03
JP5508384B2 (ja) 2014-05-28
CO6300864A2 (es) 2011-07-21
CA2719118A1 (fr) 2009-12-03
JP2011515381A (ja) 2011-05-19
MA32248B1 (fr) 2011-04-01
CL2009000699A1 (es) 2010-04-09
KR20100124830A (ko) 2010-11-29
NZ588083A (en) 2012-07-27
IL208247A0 (en) 2010-12-30
UY31730A (es) 2009-11-10
TW200942541A (en) 2009-10-16
FR2928924A1 (fr) 2009-09-25
US8088765B2 (en) 2012-01-03
ME01112B (me) 2012-12-20
AU2009253232B2 (en) 2013-07-11
US20120053202A1 (en) 2012-03-01
US20110065700A1 (en) 2011-03-17
US8598166B2 (en) 2013-12-03
WO2009144392A1 (fr) 2009-12-03
ZA201006725B (en) 2011-11-30
AR070995A1 (es) 2010-05-19
EA201071111A1 (ru) 2011-08-30
CN103145747A (zh) 2013-06-12
FR2928924B1 (fr) 2010-04-23
CA2719118C (fr) 2016-07-26
PH12012501817A1 (en) 2013-09-02

Similar Documents

Publication Publication Date Title
CN103145747B (zh) 6-杂芳基咪唑并[1,2-a]吡啶的多取代衍生物及其制备方法和治疗用途
CN102036987B (zh) 2-杂芳基-6-苯基咪唑并[1,2-a]吡啶的多取代衍生物及其制备方法和治疗用途
JP5336378B2 (ja) ２−アリール−６−フェニルイミダゾ［１，２−α］ピリジン誘導体、これらの調製およびこれらの治療的使用
CN101959886A (zh) 咪唑并[1,2-a]吡啶-2-甲酰胺衍生物、其制备方法及其治疗应用
CN101910172A (zh) N-杂环咪唑并[1，2-a]吡啶-2-甲酰胺衍生物、其制备方法及其治疗应用
CN101959884B (zh) 6-杂环咪唑并[1，2-a]吡啶-2-甲酰胺衍生物、其制备方法和治疗用途
CN101910173A (zh) 2-杂芳酰基咪唑并[1,2-a]吡啶衍生物、其制备方法和治疗用途
CN101959885A (zh) N-杂环基-6-杂环基-咪唑并[1，2-a]吡啶-2-甲酰胺衍生物、其制备方法和其治疗用途
HK1155730A (en) Polysubstituted derivatives of 6-heteroaryl-imidazo[1,2-a] pyridines, and preparation and therapeutic use thereof
HK1148018A (en) Imidazo[1,2-a]pyridine-2-carboxamide derivatives, preparation thereof and application thereof in therapeutics
HK1148017A (en) Derivatives of n-heterocyclic-6-heterocyclic-imidazo[1,2-a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof
HK1146593A (en) Derivatives of 2-heteroaroyl-imidazol[1,2-a]pyridine, preparation thereof and therapeutic application thereof
HK1155454A (en) Polysubstituted derivatives of 2-heteroaryl-6-phenyl-imidazo[1,2-a] pyridines, and preparation and therapeutic use thereof
HK1148016B (en) Derivatives of 6-heterocyclic-imidazo[1,2-a]pyrroine-2-carboxamides, preparation thereof and therapeutic application thereof
HK1146629A (en) 2-benzoylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof
HK1146594A (en) Derivatives of n-heterocyclic-imidazo[1,2-a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1155730

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1155730

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140507

Termination date: 20180320